Cargando…

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors

The discovery and development of erythropoiesis-stimulating agents was a journey lasting more than a century, leading to the cloning and approval of recombinant human erythropoietin (rHuEpo). This was an impressive clinical advance, providing the possibility of correcting the symptoms associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locatelli, Francesco, Del Vecchio, Lucia, Elliott, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	CKJ Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539216/ https://www.ncbi.nlm.nih.gov/pubmed/37779852 http://dx.doi.org/10.1093/ckj/sfad105

Ejemplares similares

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2022)

Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification
por: Negri, Armando Luis
Publicado: (2022)

Systemic and targeted steroids for the treatment of IgA nephropathy
por: Locatelli, Francesco, et al.
Publicado: (2023)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

Leukocyte–endothelial interaction in CKD
por: Sarakpi, Tamim, et al.
Publicado: (2023)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007)

Thiazide diuretics are back in CKD: the case of chlorthalidone
por: Minutolo, Roberto, et al.
Publicado: (2022)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
por: Leoncini, Giovanna, et al.
Publicado: (2022)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Management of fracture risk in CKD—traditional and novel approaches
por: Haarhaus, Mathias, et al.
Publicado: (2022)

The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1–3a CKD patients
por: Zoccali, Carmine, et al.
Publicado: (2023)

The emerging role of iron in heart failure and vascular calcification in CKD
por: Ciceri, Paola, et al.
Publicado: (2020)

Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016)

Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
por: Vervloet, Marc G
Publicado: (2023)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective
por: Torreggiani, Massimo, et al.
Publicado: (2022)

Unmet needs in clinical trials in CKD: questions we have not answered and answers we have not questioned
por: Levin, Adeera, et al.
Publicado: (2022)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
por: Miao, Mengqiu, et al.
Publicado: (2022)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
por: Poloznikov, Andrey A., et al.
Publicado: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
por: Noonan, Megan L., et al.
Publicado: (2020)

Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
por: Wang, Bin, et al.
Publicado: (2020)

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
por: Hafez, Gaye, et al.
Publicado: (2023)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

Cloning of the Human MORG1 Promoter: Differential Regulation by Hypoxia and Prolyl-Hydroxylase Inhibitors
por: Bondeva, Tzvetanka, et al.
Publicado: (2022)

Intravenous iron therapy and the cardiovascular system: risks and benefits
por: Del Vecchio, Lucia, et al.
Publicado: (2020)

The Hypoxia-Inducible Factor Pathway, Prolyl Hydroxylase Domain Protein Inhibitors, and Their Roles in Bone Repair and Regeneration
por: Fan, Lihong, et al.
Publicado: (2014)

Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain
por: Chan, Mun Chiang, et al.
Publicado: (2015)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia
por: Schild, Yves, et al.
Publicado: (2023)

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016)

Citation classics: ranking of the top 100 most cited articles in nephrology
por: Montinaro, Vincenzo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_024n3r5olp35uh398p2si9t8ga